8-K: Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

Foghorn Therapeutics announces strategic objectives for 2025, highlighting progress in inhibitor and degrader programs, including FHD-909 and selective degradation of ARID1B.

Summary

• Foghorn Therapeutics is advancing its first-in-class oral selective SMARCA2 inhibitor, FHD-909, in a Phase 1 trial for SMARCA4 mutated cancers, primarily targeting non-small cell lung cancer (NSCLC).
• Preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors will be presented at the AACR Annual Meeting in April 2025.
• The company has achieved selective degradation of ARID1B and plans to provide a program update in 2025.
• Foghorn is also progressing its Selective CBP degrader and Selective EP300 degrader programs.
• As of December 31, 2024, Foghorn has $243.8 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with program advancements, a strong cash position, and a major collaboration. The focus on precision therapeutics and novel targets suggests a promising future for the company.

Positives

• FHD-909 has demonstrated high selectivity over SMARCA4 in preclinical studies.
• Preclinical data shows robust monotherapy anti-tumor activity for the Selective CBP degrader without significant side effects.
• Selective EP300 degraders are well-tolerated in vivo with no observed decrease in platelet levels.
• Foghorn has a strong balance sheet with a cash runway into 2027.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
• Actual results may differ materially from those contemplated by the forward-looking statements due to various factors, including those detailed in the company's SEC filings.

Future Outlook

Foghorn Therapeutics anticipates important progress across its inhibitor and degrader programs in 2025, with a focus on advancing FHD-909 and providing updates on its preclinical pipeline, including the Selective ARID1B degrader program. The company expects to file INDs for the Selective CBP Degrader and Selective EP300 Degrader in 2026.

Management Comments

• Adrian Gottschalk, President and Chief Executive Officer of Foghorn, stated that the company expects important progress across its inhibitor and degrader programs in 2025.
• Adrian Gottschalk mentioned excitement about the progress of the preclinical pipeline and plans to provide a program update on selective degradation of ARID1B in 2025.

Industry Context

Foghorn's focus on chromatin biology and targeted protein degradation positions it within a growing field of precision oncology. The company's collaboration with Lilly validates its approach and provides significant resources for advancing its pipeline. The challenges in selectively drugging targets like CBP and EP300 highlight the innovative nature of Foghorn's degrader platform.

Comparison to Industry Standards

• Foghorn's approach to selectively targeting SMARCA2 is notable, as the industry has historically struggled to develop selective inhibitors for this target.
• The company's selective CBP and EP300 degraders aim to overcome the toxicity issues associated with dual inhibition, a common problem in the field.
• The achievement of selective ARID1B degradation is significant, as ARID1B has been a challenging target due to its lack of enzymatic activity.

Stakeholder Impact

• Shareholders: The announcement of program progress and a strong cash position is likely to be viewed positively by shareholders.
• Employees: Advancing programs and a solid financial foundation can boost employee morale and job security.
• Patients: Progress in developing novel cancer therapies offers hope for improved treatment options.

Next Steps

• Present preclinical combination data for FHD-909 at the AACR Annual Meeting in April 2025.
• Provide a program update on the Selective ARID1B degrader program in 2025.
• Advance Selective CBP degrader and Selective EP300 degrader programs.
• File INDs for Selective CBP Degrader and Selective EP300 Degrader in 2026.

Key Dates